{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:25Z","timestamp":1783075945985,"version":"3.54.6"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00691","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:09:47Z","timestamp":1590037787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer\u2019s Dementia Are Frequently Below the Recommended Levels"],"prefix":"10.3389","volume":"11","author":[{"given":"Marion","family":"Ortner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Stange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Goldhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Diehl-Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"F\u00f6rstl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Steimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001191.pub3","article-title":"Rivastigmine for Alzheimer's disease","volume":"9","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume-title":"Cochrane Database Syst. Rev.","author":"Birks","year":"2006"},{"key":"B3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease","volume":"16","author":"Blesa","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.kjms.2017.04.006","article-title":"Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan","volume":"33","author":"Chen","year":"2017","journal-title":"Kaohsiung J. Med. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3233\/JAD-2012-120109","article-title":"Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients","volume":"31","author":"Chou","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00228-016-2033-1","article-title":"Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease","volume":"72","author":"Coin","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156720510790274455","article-title":"Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies","volume":"7","author":"Darreh-Shori","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00702-006-0526-2","article-title":"Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment","volume":"113","author":"Darreh-Shori","year":"2006","journal-title":"J. Neural Transm (Vienna)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-130845","article-title":"Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors","volume":"39","author":"Darreh-Shori","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B12","volume-title":"W, S3-Leitiline Demenz.","author":"Deuschl","year":"2016"},{"key":"B13","article-title":"A NICE-SCIE Guideline on Supporting People With Dementiaand Their Carers in Health and Social Care","year":"2007"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1212\/WNL.56.9.1154","article-title":"Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"56","author":"Doody","year":"2001","journal-title":"Neurology"},{"key":"B15","first-page":"884","article-title":"Clinical practice guidelines and principles of care for people with dementia in Australia","volume":"45","author":"Dyer","year":"2016","journal-title":"Aust. Fam Phys."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","article-title":"Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study","volume":"32","author":"Farlow","year":"2010","journal-title":"Clin. Ther."},{"key":"B17","article-title":"NDA 22-083\/ S016 Exelon Patch (rivastigmine trandermal system)","year":"2012"},{"key":"B18","article-title":"Aricept label information","year":"2015"},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5770\/cgj.15.49","article-title":"participants, 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia","volume":"39","author":"Gauthier","year":"2012","journal-title":"Can. J. Neurol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/FTD.0000000000000152","article-title":"Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil","volume":"37","author":"Hefner","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"B22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00007691-200408000-00019","article-title":"Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service","volume":"26","author":"Heller","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"B23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1017\/S2045796016001098","article-title":"Behavioural and psychological symptoms in general hospital patients with dementia, distress for nursing staff and complications in care: results of the General Hospital Study","volume":"27","author":"Hessler","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s00415-019-09200-8","article-title":"Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis","volume":"266","author":"Jin","year":"2019","journal-title":"J. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2011.10.027","article-title":"Implementation of a cost-effective HPLC\/UV-approach for medical routine quantification of donepezil in human serum","author":"Koeber","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. BioMed. Life Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3238\/arztebl.2017.0447","article-title":"The Diagnosis and Treatment of Behavioral Disorders in Dementia","volume":"114","author":"Kratz","year":"2017","journal-title":"Dtsch Arztebl. Int."},{"key":"B31","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","volume-title":"Cochrane Database Syst. Rev.","author":"Li","year":"2015"},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jns.2014.05.033","article-title":"Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: a meta-analysis","volume":"343","author":"Lu","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study","volume":"288","author":"Lyketsos","year":"2002","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/psyg.12140","article-title":"Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies","volume":"16","author":"Manabe","year":"2016","journal-title":"Psychogeriatrics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3233\/JAD-150175","article-title":"Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS)","volume":"46","author":"Matsuzono","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","article-title":"Molecular mechanisms of genetic polymorphisms of drug metabolism","volume":"37","author":"Meyer","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3233\/JAD-160164","article-title":"Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms","volume":"55","author":"Miranda","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jns.2016.05.001","article-title":"Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic\/pharmacodynamic analysis in a phase 3 randomized controlled trial","volume":"366","author":"Mori","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease","volume":"39","author":"Morris","year":"1989","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/bcp.12325","article-title":"Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance","volume":"78","author":"Noetzli","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00008571-200304000-00008","article-title":"Regulation of attention and response to therapy in dementia by butyrylcholinesterase","volume":"13","author":"O'Brien","year":"2003","journal-title":"Pharmacogenetics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.biopsych.2014.01.019","article-title":"Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer's disease","volume":"77","author":"Ortner","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.clpt.2004.04.009","article-title":"A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects","volume":"76","author":"Raimundo","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.158.9.1021","article-title":"Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study","volume":"158","author":"Rogers","year":"1998","journal-title":"Donepezil. Study Group Arch. Intern. Med."},{"key":"B47","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","volume-title":"Cochrane Database Syst. Rev.","author":"Rolinski","year":"2012"},{"key":"B48","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/FPC.0b013e32833f984c","article-title":"Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease","volume":"21","author":"Seripa","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jalz.2011.01.006","article-title":"Predictors of suicide in patients with dementia","volume":"7","author":"Seyfried","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000350050","article-title":"Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease","volume":"37","author":"Sonali","year":"2014","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1373\/clinchem.2003.030825","article-title":"Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers","volume":"50","author":"Steimer","year":"2004","journal-title":"Clin. Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/psyg.12197","article-title":"Neuropsychiatric symptoms in dementia may predict caregiver burden: a Sicilian exploratory study","volume":"17","author":"Torrisi","year":"2017","journal-title":"Psychogeriatrics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"v2","DOI":"10.1136\/jnnp.2005.082867","article-title":"Epidemiology and risk factors of dementia","volume":"76","author":"van der Flier","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00228-006-0168-1","article-title":"Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients","volume":"62","author":"Varsaldi","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00023210-199912040-00005","article-title":"Selectivity of Cholinesterase Inhibition","volume":"12","author":"Weinstock","year":"1999","journal-title":"CNS Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/archneur.1991.00530150046016","article-title":"Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures","volume":"48","author":"Welsh","year":"1991","journal-title":"Arch. Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JCP.0b013e31828b5087","article-title":"Concentration of donepezil to the cognitive response in Alzheimer disease","volume":"33","author":"Yang","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1001\/jama.2013.282818","article-title":"Ingredients of successful interventions to improve medication adherence","volume":"310","author":"Zullig","year":"2013","journal-title":"JAMA"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:09:51Z","timestamp":1590037791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":61,"alternative-id":["10.3389\/fphar.2020.00691"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00691","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"article-number":"691"}}